Core Insights - Gossamer Bio Inc. is identified as a penny stock with the potential for significant price appreciation, specifically a rise of 1000 percent [1] - The company faced a setback in its Phase 3 PROSERA study for seralutinib in pulmonary arterial hypertension, missing its primary endpoint, but plans to discuss future steps with the FDA [1] - Analysts from Oppenheimer and H.C. Wainwright maintain bullish ratings despite lowering their price targets, indicating strong upside potential based on current share prices [2] Analyst Ratings - Oppenheimer has maintained an Outperform rating while reducing its price target from $12 to $3, suggesting an upside of over 700% from the current share price of approximately $0.37 [2] - H.C. Wainwright has kept its Buy rating and lowered its target from $10 to $5, implying an upside of more than 1,200% [2] Probability of Success - Analyst Patrick Trucchio from H.C. Wainwright has reduced the estimated probability of success for seralutinib in PAH from 70% to 50%, yet still sees evidence of clinical activity in heavily pretreated patients [3] - There is a belief that a potential path forward for the drug may still exist, although regulatory and capital uncertainties are expected to persist [3] Company Overview - Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary hypertension and other serious diseases [4]

Core Insights - Gossamer Bio, Inc (NASDAQ:GOSS) is recognized as one of the best high-risk penny stocks to buy currently, despite mixed fourth-quarter results where earnings missed expectations but revenue exceeded them significantly [1] Financial Performance - The company reported a GAAP loss of $0.21 per share, which was $0.02 below analyst estimates [1] - Revenue for the quarter reached $13.8 million, marking a 47.8% year-over-year increase and surpassing consensus estimates by $6.28 million [1] Strategic Focus - Following the PROSERA topline results, the company is concentrating on understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic options for future positioning [2] - The PROSERA trial narrowly missed its primary endpoint, but the company believes that seralutinib shows efficacy in treating pulmonary arterial hypertension (PAH), particularly in patients with advanced disease [2] Analyst Insights - H.C. Wainwright analyst Patrick Trucchio has lowered the price target for Gossamer Bio from $10 to $5 while maintaining a Buy rating, reflecting a reduced probability of success for seralutinib from 70% to 50% [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Gossamer Bio, Inc. following a significant stock price drop after a failed clinical trial [1][3]. Group 1: Company Overview - Gossamer Bio, Inc. is a publicly traded company on NASDAQ under the ticker GOSS [1]. - The company recently announced the failure of its Phase 3 PROSERA trial for seralutinib, which was aimed at treating pulmonary arterial hypertension [3]. Group 2: Stock Performance - Following the announcement of the trial failure, Gossamer's stock price plummeted by $1.71 per share, representing a decline of 80.14%, closing at $0.423 per share on February 23, 2026 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of Gossamer investors to determine if there were any fraudulent activities or misconduct by the company's officers and directors [1].

Core Insights - Gossamer Bio, Inc. (NASDAQ:GOSS) is currently highlighted as one of the most active penny stocks to consider for investment [1] - As of March 16, 2026, 44% of analysts maintain a "Buy" rating for Gossamer Bio, with a consensus price target of $1.00, indicating an upside potential of 117.39% [2] - Recent revisions in forecasts for Gossamer Bio's primary therapy, seralutinib, are attributed to an uncertain regulatory environment [2] Analyst Ratings and Price Targets - H.C. Wainwright & Co. has maintained a "Buy" rating but reduced its price target from $10 to $5, citing a lowered probability of success for seralutinib in pulmonary arterial hypertension (PAH) from 70% to 50% [3] - Oppenheimer & Co. reiterated its "Outperform" rating while lowering its price target from $12 to $3, noting that upcoming FDA interactions and data could mitigate risks associated with seralutinib's approval pathway [4] Company Overview - Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immunology, inflammation, and oncology, with notable projects including GB001 for eosinophilic asthma [5]

Financial Data and Key Metrics Changes - In 2025, XOMA Royalty reported total GAAP income and revenue of $52.1 million, a significant increase from $28.5 million in 2024 [21] - Total cash receipts grew by 9% to $50.5 million, with royalty receipts reaching approximately $34 million, marking a 68% increase compared to 2024 [21] - Full-year GAAP net income was $31.7 million, compared to a GAAP net loss of $13.8 million in 2024 [23] Business Line Data and Key Metrics Changes - The company added 22 assets to its portfolio in 2025, including five in phase II or phase III trials, with a total cash outlay of only $25 million upfront [14] - Royalty receipts came from four programs in 2025, two more than in 2024, and six programs achieved clinical, regulatory, and business development events, leading to approximately $17 million in cash milestone payments [21] Market Data and Key Metrics Changes - The portfolio has expanded significantly, doubling the number of assets in active development from roughly 60 in 2023 to over 120 in 2025 [12] - The company has established a diverse and growing source of recurring receipts, with seven commercially available programs [5] Company Strategy and Development Direction - XOMA Royalty aims to build a diversified portfolio of biotechnology royalty and milestone assets while maintaining disciplined capital allocation [11] - The company is focused on innovative transactions and underappreciated opportunities, positioning itself as a unique source of capital for biotech innovation [20] - The strategy includes a balance between returning capital to shareholders and investing in new portfolio assets to increase breadth [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for royalty receipts, particularly from VABYSMO, OJEMDA, and MIPLYFFA, which are expected to ramp up significantly [32] - The company is approaching an inflection point where royalty receipts alone could cover operating expenses by 2027 [28] - Management remains optimistic about the potential for future milestone payments and royalty growth from a robust late-stage pipeline [9] Other Important Information - The company maintained a lean operating structure, achieving positive cash flow from operations and returning $16 million of capital through share buybacks [5] - XOMA Royalty ended the year with approximately $83 million in unrestricted cash and cash equivalents, providing ample firepower for future investments [27] Q&A Session Summary Question: Growth prospects for royalty receipts on approved products - Management indicated strong growth prospects, particularly from VABYSMO, which had double-digit growth last year, and positive expectations for OJEMDA and MIPLYFFA [32] Question: Confidence in Tremfya economic opportunity - Management expressed confidence in the breach claim related to Tremfya, citing historical relationships and potential royalty rates [34] Question: Prioritization of capital deployment between share buybacks and new deals - Management emphasized a philosophy of reducing equity base to increase cash flow per share while balancing external opportunities [46] Question: Size of the opportunity for Rezolute's ersodetug program - Management estimated the combined opportunity for the two indications to be approaching $1 billion, with a favorable split between congenital and tumor hyperinsulinism [48]

Core Viewpoint - Gossamer Bio's Phase 3 PROSERA study of seralutinib missed its primary endpoint, leading to significant shareholder losses, despite prior optimism expressed by the CEO regarding the trial's potential success [1][3]. Group 1: Trial Results and Company Statements - The PROSERA study's primary endpoint was the 6-minute walk distance in patients with pulmonary arterial hypertension, which it failed to meet, with a p-value of 0.032 not reaching the significance threshold of 0.025 [3]. - CEO Faheem Hasnain had previously stated that the patient population enrolled in the trial was more severe than in the TORREY study and expressed confidence in the trial's statistical power of over 90% [2]. - The company had projected to deliver top-line results in February 2026, which ultimately revealed the trial's failure [2]. Group 2: Legal Investigation - Levi & Korsinsky, LLP is investigating whether Gossamer Bio's prior statements regarding trial confidence, statistical power, and patient baseline characteristics were accurate at the time they were made [3]. - Shareholders who suffered losses are encouraged to submit their information for potential legal recourse [4].

CORPORATE PRESENTATION NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions with significant financial implications, collaborations poised for s ...

Core Insights - Gossamer Bio, Inc. experienced a significant decline of over 60% in its stock value following the Phase 3 PROSERA trial results for seralutinib, which missed its primary endpoint [1] - The company's CEO had previously set expectations for positive results in February 2026, indicating optimism about the trial's outcome [1] - The trial's statistical plan required a significance level of alpha = 0.025, which was not disclosed to investors, leading to a gap between management's guidance and the actual statistical requirements [1] Company Performance - The actual p-value from the PROSERA trial was reported at 0.032, which, while passing the conventional 0.05 threshold, did not meet the more stringent 0.025 requirement [1] - The lack of disclosure regarding the heightened statistical threshold created an elevated risk for investors who relied on the company's forward-looking statements [1] Investor Impact - Shareholders who invested in Gossamer Bio and incurred losses are encouraged to seek legal advice regarding their rights [1] - The investigation focuses on the discrepancy between the company's optimistic guidance and the undisclosed statistical hurdles that contributed to the trial's failure [1]

NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 CORPORATE PRESENTATION XOMA ROYALTY – WHAT WE DO Royalties Milestones Science Structuring DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions w ...

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]